Samson assumes the role of interim president following the departure of
Dr. Helen Giles-Gee in December 2014. Samson has been a committed advocate of
University of the Sciences since joining its board of trustees in 1991. He has
served as chairman of USciences’ board of trustees since 2011 and was the
University’s interim president for the 2011-12 academic year.
the founder and CEO of Samson Medical Technologies, LLC, a company specializing
in injectable drug delivery systems and programs for hospital and alternate
site pharmacists. A native of Philadelphia, Samson received his bachelor of
science in chemistry from Temple University.
In 1967, Samson helped to found Elkins-Sinn,
today, West-Ward Pharmaceuticals, and was its president and CEO for 18 years.
Following that, he was the founder, president, and CEO of Marsam
Pharmaceuticals; joined SICOR as president and CEO and following Sicor’s
acquisition by Teva was Teva’s group VP of worldwide injectables; was board
chairman and CEO of Qualitest Pharmaceuticals; and was board chairman of JHP
Samson holds five U.S. patents pertaining to
pharmaceutical manufacturing. He also is active on numerous charitable and
industry boards. He is a member of the board of directors of Virtua Health
System, NanoPass Technologies, Flynn Pharma, The Franklin Institute, Cooper
Rowan Medical School, and Antares Pharma Inc.
A recipient of various awards for business
leadership, Samson continues to serve the community through charitable support
of educational institutions, hospitals, healthcare research and development,
and children’s programs. A resident of Palm Beach, FL, Samson has three children
and seven grandchildren.